Experiences with
Tirosint762 public posts
Drug Submission time again. We are looking to speak to anyone who has experience of Loratinib (Lorviqua)
lorlatinib (Lorviqua) will shortly be assessed by the Scottish Medicines Consortium (SMC) for use in NHSScotland, and to invite you to provide a Patient Group Submission for the medicine.
The indication this new medicine will be assessed under is: "As monotherapy is indicated for the treatment of
Want to take advantage of all our features? Just log in!
or
PJP prophylaxis may be unnecessary for CLL patients on BTK inhibitors
From a report from the recent Edinburgh iWCLL 2019, [i]"Routine empiric prophylaxis against pneumocystis jiroveci pneumonia (PJP) may be unwarranted in chronic lymphocytic leukemia patients initiating Bruton tyrosine kinase (BTK) inhibitor therapy, a retrospective chart review suggests."[/i]
Dr. Ryan
A Conversation with Dr Tam about Zanubrutinib: A Novel BTK Inhibitor
How does zanubrutinib differ from ibrutinib in pharmacokinetics and target occupancy?
Zanubrutinib has a more-specific target binding profile than ibrutinib. It binds to BTK at least as potently as ibrutinib. Zanubrutinib has fewer off-target effects on related enzymes, including the epidermal growth